Zalicus Pharmaceuticals Ltd.
Records under this name other than patents Zalicus Pharmaceuticals Ltd. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned.
Back to Zalicus Pharmaceuticals Ltd.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,377,968 | N-Piperidinyl Acetamide Derivatives as Calcium Channel Blockers Formerly held In force · High confidence | In force | High confidence | |
| US 8,569,344 | N-Piperidinyl Acetamide Derivatives as Calcium Channel Blockers Formerly held In force · High confidence | In force | High confidence | |
| US 9,096,522 | N-Piperidinyl Acetamide Derivatives as Calcium Channel Blockers Formerly held In force · High confidence | In force | High confidence | |
| US 9,688,615 | Benzimidazole inhibitors of the sodium channel Formerly held In force · From the USPTO record | In force | From the USPTO record | |
| US 10,208,023 | Heterocyclic inhibitors of the sodium channel Formerly held In force · From the USPTO record | In force | From the USPTO record | |
| US 6,294,533 | Calcium channel blockers Term ended Term ended Sep 23, 2019 · From the USPTO record | Term ended | Term ended Sep 23, 2019 | From the USPTO record |
| US 6,011,035 | Calcium channel blockers Term ended Term ended Jun 29, 2018 · From the USPTO record | Term ended | Term ended Jun 29, 2018 | From the USPTO record |
| US 6,387,897 | Preferentially substituted calcium channel blockers Term ended Ended no later than Jun 29, 2018 · From the USPTO record | Term ended | Ended no later than Jun 29, 2018 | From the USPTO record |
| US 7,666,865 | Calcium channel blockers Lapsed on the fee record Ended Feb 23, 2018 · From the USPTO record | Lapsed on the fee record | Ended Feb 23, 2018 | From the USPTO record |
| US 7,659,395 | Urea derivatives as calcium channel blockers Lapsed on the fee record Ended Feb 9, 2018 · From the USPTO record | Lapsed on the fee record | Ended Feb 9, 2018 | From the USPTO record |